Prostate Cancer Discoveries Digest Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship. See all Newsletters Jump To Jump To Join the Email List Welcome to the May 2025 edition of ZERO’s Prostate Cancer Discoveries Digest! We’ve gathered the latest headlines on prostate cancer treatment, diagnostics, side effects, and more—delivered straight to your inbox. Know someone who could benefit from these updates? Forward this newsletter and help spread the word. ZERO Prostate Cancer does not endorse any particular study or finding in this issue. Screening Polygenic Risk Score for Prostate Cancer Screening A new study found that using polygenic risk scores for prostate cancer screening identified more clinically significant cancers than traditional PSA and MRI-based screening. » Full Article from ASCO Post Genetics & Genomics New Insight into Genetic Drivers of Prostate Cancer A large international study revealed how inherited and acquired genetic changes interact to drive prostate cancer progression; these findings highlight new opportunities for precision diagnostics and treatment. » Full Article from Renal+Urology News Treatment A Survey Analysis of Urologists' Evolving Attitudes Toward Focal Therapy for Prostate Cancer A survey found that focal therapy is gaining traction among U.S. urologists as a prostate cancer treatment option. » Full Article from UroToday Outcomes Early Oncological Outcomes of Very High-Risk Prostate Cancer Patients According to the STAMPEDE Trial Definition New research shows that very high-risk prostate cancer patients had better early oncologic outcomes when staged with PSMA PET compared to conventional imaging. » Full Article from UroToday Treatment Phase 3 Trial of Capivasertib Discontinued The Phase 3 trial studying capivasertib for the treatment of patients with mCRPC was discontinued after it was determined that the study was unlikely to meet its goals for radiographic progression-free survival and overall survival. » Full Article from Urology Times Genetics & Genomics Somatic Tumor Next-Generation Sequencing in US Veterans with Metastatic Prostate Cancer In a large study involving Veterans with metastatic prostate cancer, researchers found racial differences in genomic alterations. » Full Article from JAMA Network Treatment Systemic Therapy in Patients with mCRPC ASCO recently updated its guidelines for clinicians in the treatment of systemic therapy for patients with mCRPC. While these guidelines are intended for medical professionals, patients and their loved ones may find it—and the accompanying podcast—helpful for understanding how it shapes treatment options. » Full Article from ASCO Publications Outcomes Treatment Patterns and Outcomes for Younger Patients with mCRPC A new study in Australia found that patients diagnosed with mCRPC before age 55 had treatment patterns and outcomes similar to older patients. This is encouraging news, as it suggests age alone does not determine the success of treatment or lead to better clinical outcomes. » Full Article from UroToday ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan. Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
Welcome to the May 2025 edition of ZERO’s Prostate Cancer Discoveries Digest! We’ve gathered the latest headlines on prostate cancer treatment, diagnostics, side effects, and more—delivered straight to your inbox. Know someone who could benefit from these updates? Forward this newsletter and help spread the word. ZERO Prostate Cancer does not endorse any particular study or finding in this issue. Screening Polygenic Risk Score for Prostate Cancer Screening A new study found that using polygenic risk scores for prostate cancer screening identified more clinically significant cancers than traditional PSA and MRI-based screening. » Full Article from ASCO Post Genetics & Genomics New Insight into Genetic Drivers of Prostate Cancer A large international study revealed how inherited and acquired genetic changes interact to drive prostate cancer progression; these findings highlight new opportunities for precision diagnostics and treatment. » Full Article from Renal+Urology News Treatment A Survey Analysis of Urologists' Evolving Attitudes Toward Focal Therapy for Prostate Cancer A survey found that focal therapy is gaining traction among U.S. urologists as a prostate cancer treatment option. » Full Article from UroToday Outcomes Early Oncological Outcomes of Very High-Risk Prostate Cancer Patients According to the STAMPEDE Trial Definition New research shows that very high-risk prostate cancer patients had better early oncologic outcomes when staged with PSMA PET compared to conventional imaging. » Full Article from UroToday Treatment Phase 3 Trial of Capivasertib Discontinued The Phase 3 trial studying capivasertib for the treatment of patients with mCRPC was discontinued after it was determined that the study was unlikely to meet its goals for radiographic progression-free survival and overall survival. » Full Article from Urology Times Genetics & Genomics Somatic Tumor Next-Generation Sequencing in US Veterans with Metastatic Prostate Cancer In a large study involving Veterans with metastatic prostate cancer, researchers found racial differences in genomic alterations. » Full Article from JAMA Network Treatment Systemic Therapy in Patients with mCRPC ASCO recently updated its guidelines for clinicians in the treatment of systemic therapy for patients with mCRPC. While these guidelines are intended for medical professionals, patients and their loved ones may find it—and the accompanying podcast—helpful for understanding how it shapes treatment options. » Full Article from ASCO Publications Outcomes Treatment Patterns and Outcomes for Younger Patients with mCRPC A new study in Australia found that patients diagnosed with mCRPC before age 55 had treatment patterns and outcomes similar to older patients. This is encouraging news, as it suggests age alone does not determine the success of treatment or lead to better clinical outcomes. » Full Article from UroToday ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan.
Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
